• Strong collaboration between AIFA, Clinicians, Hospital Pharmacists, Pharmacologists, Payers (Regional and Local) and pharmaceutical companies is needed through the Registries management (i.e., prescription, purchasing process, effectiveness evaluation)
• Registries permit to collect real world data to re-assess the clinical value in clinical practice (i.e., effectiveness) enabling a value-based pricing approach.
• For all stakeholders, registries represent an opportunity to work together in the light of partnership and sustainability.
• As an example of implementation of conditional agreement based on AIFA registries, we report the re-negotiation process of pirfenidone in the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).
• Pirfenidone had its first reimbursement authorization in 2013 with a risk-sharing agreement (Success Fee) and drug inclusion in the AIFA Registry.
• Web-based AIFA Registry is a Web-based tool, created by AIFA on a drug specific bases, allowing:
-Clinicians to register patients ensuring the eligibility of the patient and his monitoring;
-Hospital pharmacist to dispense the drug within NHS funds;
-AIFA to collect data to evaluate drug effectiveness in real practice -Companies to manage innovative pricing schemes (ie. cost-sharing, payment by results)
• Risk sharing agreement based upon CAPACITY trial study results was the result of the first negotiation in 2013.
-Based on the agreement, patients presenting a FVC≥10% decline at 6 month follow up (i.e., decline of 10 percentage calculated as delta from day 0 of therapy) were not allowed to continue the treatment with pirfenidone and initial 6 months were paid by the company.
Conclusions
When the risk/benefit ratio is not yet been sufficiently defined, this approach allows to reduce uncertainties and to re-assess health technologies in line with health policies.
At present AIFA negotiated with Pharmaceutical companies more than 120 registries.
It is expected that in the future there will be an increased use of data collected through AIFA Registers for reassessment of innovative therapies. • New Phase III RCT data 2,3 and clinical practice 4 data strengthening pirfenidone value were submitted for the re-negotiation to reassess the cost-benefit profile:
1. Data from ASCEND study shows:
• Treatment with pirfenidone significantly reduced disease progression, as measured by changes in % predicted FVC (p<0.000001) (Fig.1) • Changes in 6-minute walk distance (p=0.036)
• Treatment with pirfenidone reduced all-cause mortality in a pre-specified pooled analyses at week 52 (p=0.011) 2. Pre-specified pooled analysis of data from CAPACITY and ASCEND studies demonstrate that even patients experiencing ≥10% FVC decline in the first 6 months benefit from treatment continuation (Fig. 2) 3. Data form a RWE 4 cohort of patients confirmed effectiveness of pirfenidone:
• Largest real life data cohort ( n=197) of pirfenidone in IPF,
• Includes 113 patients from Turin University Clinic
• Endpoints: Analysis of change of FVC before and after start of treatment with pirfenidone (Fig. 3) -FVC decline before treatment -7,0 ± 1,8% (-248,1 ± 199,3 ml per year) -FVC decline with Pirfenidone therapy (+2,7 ± 3,6% o +51,4 ± 351,4 ml per anno) (p<0,0001) 4. Data from AIFA registry effectiveness and tolerability were positively perceived during the renegotiation
• Thanks to these evidences, the uncertainty around the benefit in clinical practice was overcome; AIFA agreed to withdraw the risk-sharing; the drug is still available in AIFA Registry to monitor the appropriateness of use. As a result:
-Stopping rules were removed from the registry (Fig. 4) -Drug effectiveness continue to be collected through registry to consolidate information to define product value
Results

Discussion
Data collected through AIFA registries supplemented with ASCEND data and RWE data allow both Agency and Company to re-assess pirfenidone value.
Pre specified ASCEND pooled Analysis and Pooled data from registry allow to understand that FVC≥10% decline within 6 month is not a direct proxy of drug effectiveness.
Analysis
Pirfenidone
N=623
Placebo
N=624
Difference
Proportion experiencing a ≥10% decline in months 1-6 4.9% 9.5% P<0.001
Of those who experienced a ≥10% decline in months 1-6, proportion who died up to month 12 6.7% 28.9% P=0.016 
